Our Science
FoRx Therapeutics studies DNA replication stress, a tightly regulated process critical for accurate genome duplication.
forxtherapeutics.comCrawled Nov 3, 2026
FoRx Therapeutics studies DNA replication stress, a tightly regulated process critical for accurate genome duplication.
FoRx Therapeutics’ pipeline includes FORX-428, a clinical-stage PARG inhibitor targeting treatment-resistant cancers.
FoRx Therapeutics presents its scientific work at international conferences, including the AACR Annual Meeting 2026 in San Diego, USA.
FoRx Therapeutics presents its scientific work at international conferences, including ESMO Congress 2026 in Madrid, Spain.
Basel, Switzerland, 11 August 2025 – FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response.
FoRx Therapeutics shares updates on scientific discoveries, pipeline progress, and corporate developments in oncology.
FORX-428, a PARG inhibitor, shows high potency in preclinical models of PARP inhibitor-resistant cancers.
The board of FoRx Therapeutics includes leaders with expertise in life sciences investment, preclinical research, and oncology commercialization.
The founders of FoRx Therapeutics specialize in DNA replication stress, translational biology, and clinical development.
The leadership team at FoRx Therapeutics combines decades of experience in oncology drug discovery and clinical development from pharmaceutical and biotechnology companies.
FoRx Therapeutics welcomes partnership inquiries, investment opportunities, and academic collaborations.
FoRx Therapeutics develops precision therapeutics targeting DNA replication stress in treatment-resistant cancers.
FoRx Therapeutics invites inquiries from partners, investors, and collaborators interested in advancing therapeutics.
FoRx Therapeutics presents preclinical data at the **ACS Spring 2026** meeting, highlighting **FORX-428**, a **PARG inhibitor** in **Phase 1 development**. The company’s findings emphasize FORX-428’s potential as a best-in-class candidate, supported by molecular structure and efficacy data. FoRx focuses on precision anti-cancer therapeutics, positioning FORX-428 as a novel approach in oncology.
FoRx Therapeutics AG secures **US$50 million in Series A funding** to develop its **PARG inhibitor** drug candidate. The financing follows a **US$10 million seed round** raised in 2020, accelerating the company’s pipeline in oncology. The biotech focuses on targeting **PARG (poly(ADP-ribose) glycohydrolase)**, a protein linked to cancer progression.
FoRx Therapeutics secures a **USD 50 million Series A funding round** led by insiders to advance its **PARG inhibitor**, a precision anti-cancer therapy. The capital enables the company to generate clinical data for its potential best-in-class treatment. FoRx focuses on developing targeted cancer therapeutics in the clinical-stage pipeline.
FoRx Therapeutics begins dosing the first patient in a clinical trial of **FORX-428**, a novel **PARP inhibitor** targeting the **DNA Damage Response (DDR)** in advanced solid tumors. The drug aims to disrupt tumor repair mechanisms by inhibiting **PARG**, a key enzyme in DDR pathways. This marks the company’s first human trial for FORX-428, advancing its pipeline of precision oncology therapies.
FoRx Therapeutics secures **EUR 10 million in seed funding** to advance **DNA-repair-targeting cancer therapies**. The Swiss biotech focuses on developing novel drugs designed to exploit vulnerabilities in cancer cell DNA repair mechanisms. This funding supports early-stage research and drug development in oncology.
FoRx Therapeutics AG secures a **EUR 10 million seed round** from investors including M Ventures (Merck’s VC arm), Novartis Venture Fund, and Omega Funds. The company pioneers a **first-in-class pipeline of cancer drugs targeting DNA replication stress (DRS) pathways**, a novel mechanism in oncology. FoRx’s approach focuses on addressing unmet needs in tumor treatment by modulating replication stress in cancer cells.